Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R P A'Hern

Showing results (1-10 of 69) with videos related to

Pageof 7
Sort By:
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 20, 2018
Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard RatiosR P A'Hern
Statistics in Medicine|March 17, 2001
Sample size tables for exact single-stage phase II designsR P A'Hern
British Journal of Urology|January 1, 1995
Statistical power: a measure of the quality of a studyR P A'Hern
Anticancer Research|September 1, 1987
Meta-analysis of cancer trials: a new approach to the assessment of treatmentR P A'Hern, S Ebbs
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1995
Impact of doxorubicin on survival in advanced ovarian cancerR P A'Hern, M E Gore
Lancet (London, England)|February 16, 1991
How does tamoxifen interact with chemotherapy?R P A'Hern, M Baum, M Dowsett
The British Journal of Radiology|November 7, 2000
An audit of outcome of adjuvant post-operative radiotherapy for 52 women with stage II carcinoma of the endometriumP Blake, N Lodge, R P A'Hern
Lancet (London, England)|April 27, 1985
Tamoxifen therapy, oestrogen receptor status, and postmenopausal breast cancerR P A'Hern, A J Wilson, M Baum
BMJ (Clinical Research Ed.)|December 18, 1993
Was Young's syndrome caused by exposure to mercury in childhood?W F Hendry, R P A'Hern, P J Cole
British Journal of Cancer|April 1, 1993
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimensR P A'Hern, I E Smith, S R Ebbs
Pageof 7

Showing results (1-10 of 69) with videos related to

Sort By:
Pageof 7
Clinical Oncology (Royal College of Radiologists (Great Britain))|May 20, 2018
Cancer Biology and Survival Analysis in Cancer Trials: Restricted Mean Survival Time Analysis versus Hazard RatiosR P A'Hern
Statistics in Medicine|March 17, 2001
Sample size tables for exact single-stage phase II designsR P A'Hern
British Journal of Urology|January 1, 1995
Statistical power: a measure of the quality of a studyR P A'Hern
Anticancer Research|September 1, 1987
Meta-analysis of cancer trials: a new approach to the assessment of treatmentR P A'Hern, S Ebbs
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 1, 1995
Impact of doxorubicin on survival in advanced ovarian cancerR P A'Hern, M E Gore
Lancet (London, England)|February 16, 1991
How does tamoxifen interact with chemotherapy?R P A'Hern, M Baum, M Dowsett
The British Journal of Radiology|November 7, 2000
An audit of outcome of adjuvant post-operative radiotherapy for 52 women with stage II carcinoma of the endometriumP Blake, N Lodge, R P A'Hern
Lancet (London, England)|April 27, 1985
Tamoxifen therapy, oestrogen receptor status, and postmenopausal breast cancerR P A'Hern, A J Wilson, M Baum
BMJ (Clinical Research Ed.)|December 18, 1993
Was Young's syndrome caused by exposure to mercury in childhood?W F Hendry, R P A'Hern, P J Cole
British Journal of Cancer|April 1, 1993
Chemotherapy and survival in advanced breast cancer: the inclusion of doxorubicin in Cooper type regimensR P A'Hern, I E Smith, S R Ebbs
Pageof 7